TRICIDA INC (TCDA) Stock Price, Forecast & Analysis
USA - NASDAQ:TCDA - US89610F1012 - Common Stock
TCDA Key Statistics, Chart & Performance
The current stock price of TCDA is 0.108 USD. In the past month the price decreased by -34.62%. In the past year, price decreased by -98.91%.
TCDA Latest News, Press Relases and Analysis
TCDA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.04 | 874.88B | ||
| JNJ | JOHNSON & JOHNSON | 17.97 | 449.32B | ||
| MRK | MERCK & CO. INC. | 9.79 | 215.51B | ||
| PFE | PFIZER INC | 7.63 | 138.90B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.12 | 95.03B | ||
| ZTS | ZOETIS INC | 18.97 | 53.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 22.49B | ||
| VTRS | VIATRIS INC | 4.34 | 11.80B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.39 | 10.68B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.77 | 7.77B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.89B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 3.77B |
Related stock screener links
About TCDA
Company Profile
Tricida, Inc. is a pharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 57 full-time employees. The company went IPO on 2018-06-28. TRC101, is a non-absorbed, orally administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI), tract. Its Veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. The company is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. The firm's VALOR-CKD trial is a randomized, double-blind, placebo-controlled, time-to-event trial.
Company Info
TRICIDA INC
7000 Shoreline Court, Suite 201
South San Francisco CALIFORNIA 94080 US
CEO: Gerrit Klaerner
Employees: 57
Phone: 14154297800.0
TRICIDA INC / TCDA FAQ
What does TRICIDA INC do?
Tricida, Inc. is a pharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 57 full-time employees. The company went IPO on 2018-06-28. TRC101, is a non-absorbed, orally administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI), tract. Its Veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. The company is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. The firm's VALOR-CKD trial is a randomized, double-blind, placebo-controlled, time-to-event trial.
Can you provide the latest stock price for TRICIDA INC?
The current stock price of TCDA is 0.108 USD. The price decreased by -10% in the last trading session.
What is the dividend status of TRICIDA INC?
TCDA does not pay a dividend.
How is the ChartMill rating for TRICIDA INC?
TCDA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of TRICIDA INC (TCDA)?
TRICIDA INC (TCDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.36).
Should I buy TCDA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TCDA.
When does TRICIDA INC (TCDA) report earnings?
TRICIDA INC (TCDA) will report earnings on 2023-03-27.
TCDA Technical Analysis
TCDA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TCDA. TCDA has a bad profitability rating. Also its financial health evaluation is rather negative.
TCDA Financial Highlights
Over the last trailing twelve months TCDA reported a non-GAAP Earnings per Share(EPS) of -2.36. The EPS increased by 32.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TCDA Forecast & Estimates
8 analysts have analysed TCDA and the average price target is 19.72 USD. This implies a price increase of 18159.26% is expected in the next year compared to the current price of 0.108.